• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

全面准入？市场准入与卫生技术评估发展综述：第7部分。

Access in all areas? A round up of developments in market access and health technology assessment: part 7.

作者信息

Ramagopalan Sreeram V, Pannelay Annie Jullien

机构信息

Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK.

ProductLife Group, 10 Avenue de l'Arche, 92400 Courbevoie, France.

出版信息

J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.

DOI:10.57264/cer-2025-0043
PMID:40223528
Abstract

In this update, we discuss the implementation progress of the Medicare Drug Price Negotiation Program, with particular focus on the second round of negotiations for 15 additional Part D drugs; explore the role of health technology assessment in US commercial health plan decision-making; and examine significant changes to pharmaceutical pricing systems in Germany, where international reference pricing has been eliminated as part of the Medical Research Act.

摘要

在本次更新中，我们讨论了医疗保险药品价格谈判计划的实施进展，特别关注另外15种D部分药品的第二轮谈判；探讨卫生技术评估在美国商业健康保险计划决策中的作用；并审视德国药品定价体系的重大变化，在德国，作为《医学研究法》的一部分，国际参考定价已被取消。

相似文献

1
Access in all areas? A round up of developments in market access and health technology assessment: part 7.全面准入？市场准入与卫生技术评估发展综述：第7部分。
J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.
2
Access in all areas? A round up of developments in market access and health technology assessment: part 2.全覆盖？市场准入和卫生技术评估发展综述：第 2 部分。
J Comp Eff Res. 2023 Dec;12(12):e230162. doi: 10.57264/cer-2023-0162. Epub 2023 Nov 2.
3
PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.PDP 还是 MA-PD？CMS 第 25 区的医疗保险部分 D 注册决策。
Res Social Adm Pharm. 2010 Jun;6(2):130-42. doi: 10.1016/j.sapharm.2010.04.002.
4
Lowering Part D drug costs without direct CMS negotiations.在没有医疗保险和医疗补助服务中心（CMS）直接谈判的情况下降低D部分药品成本。
Manag Care. 2009 Sep;18(9):11-2.
5
Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.比较效果分析和集体价格谈判实施后，美国和德国的药品价格差距不断扩大。
J Manag Care Spec Pharm. 2019 Dec;25(12):1310-1317. doi: 10.18553/jmcp.2019.25.12.1310.
6
Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.与独立药房所有者对医疗保险处方药部分合同满意度相关的因素。
Res Social Adm Pharm. 2010 Jun;6(2):121-9. doi: 10.1016/j.sapharm.2010.03.004. Epub 2010 May 7.
7
Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025.预计将在 2025 年被纳入医疗保险药品价格谈判计划的药物。
J Manag Care Spec Pharm. 2024 Nov;30(11):1203-1210. doi: 10.18553/jmcp.2024.24167. Epub 2024 Sep 19.
8
Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.为什么法国在药品上的支出比美国少：药品定价和定价监管的比较研究。
Milbank Q. 2021 Mar;99(1):240-272. doi: 10.1111/1468-0009.12507.
9
Examining Opportunities to Increase Savings From Medicare Price Negotiations.审视增加 Medicare 价格谈判节省机会。
JAMA Intern Med. 2023 Jun 1;183(6):581-588. doi: 10.1001/jamainternmed.2023.0763.
10
Pharmaceuticals and Medical Devices: Medicare Part D.药品和医疗器械：医疗保险D部分
Issue Brief Health Policy Track Serv. 2015 Dec 28:1-31.

引用本文的文献

1
Access in all areas? A round up of developments in market access and health technology assessment: part 8.全面准入？市场准入与卫生技术评估进展综述：第8部分。
J Comp Eff Res. 2025 Aug;14(8):e250091. doi: 10.57264/cer-2025-0091. Epub 2025 Jun 17.
2
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.我们准备好申请报销了吗？与卫生技术评估相关的真实世界证据发展综述：第19部分。
J Comp Eff Res. 2025 Jul;14(7):e250063. doi: 10.57264/cer-2025-0063. Epub 2025 May 12.

本文引用的文献

1
Use of health technology assessments in specialty drug coverage decisions by US commercial health plans.美国商业健康保险计划在专科药物覆盖范围决策中对健康技术评估的使用。
J Manag Care Spec Pharm. 2025 Mar;31(3):289-295. doi: 10.18553/jmcp.2025.31.3.289.
2
Access in all areas? A roundup of developments in market access and health technology assessment: part 6.全面准入？市场准入与卫生技术评估进展综述：第6部分。
J Comp Eff Res. 2025 Mar;14(3):e240239. doi: 10.57264/cer-2024-0239. Epub 2025 Jan 10.
3
Predicting the next round of drugs for Medicare price negotiation.
预测医疗保险价格谈判的下一轮药品
Sci Transl Med. 2024 Dec 4;16(776):eadq5711. doi: 10.1126/scitranslmed.adq5711.
4
Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025.预计将在 2025 年被纳入医疗保险药品价格谈判计划的药物。
J Manag Care Spec Pharm. 2024 Nov;30(11):1203-1210. doi: 10.18553/jmcp.2024.24167. Epub 2024 Sep 19.
5
Access in all areas? A round up of developments in market access and health technology assessment: part 2.全覆盖？市场准入和卫生技术评估发展综述：第 2 部分。
J Comp Eff Res. 2023 Dec;12(12):e230162. doi: 10.57264/cer-2023-0162. Epub 2023 Nov 2.